Company Description
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
| Country | Canada |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | William Williams |
Contact Details
Address: Bellevue Centre, Suite 300 West Vancouver, BC V7T 2X1 Canada | |
| Phone | 604-921-1810 |
| Website | briacell.com |
Stock Details
| Ticker Symbol | BCTX |
| Exchange | NASDAQ |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001610820 |
| CUSIP Number | 10778Y302 |
| ISIN Number | CA1079301091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams M.D. | Chief Executive Officer, President and Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2025 | 8-K | Current Report |
| Feb 10, 2025 | SCHEDULE 13G | Filing |
| Feb 6, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |
| Feb 4, 2025 | 424B5 | Filing |
| Feb 3, 2025 | 424B5 | Filing |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 8-K | Current Report |
| Jan 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |